Member Info for whitto

big for prem buysVolume Value
26-Jun-20 16:37:16 0.085 20,000,000 17.00k O
26-Jun-20 16:35:01 0.0848 10,000,000 8,480

19 Depth
MO 50,000 07:56
8 1,200 07:50
8 38,000 07:52
8.5 60,000 07:52
8.6 12,900 07:50
8.88 15,000 07:50
9 200,000 WINS 07:50
9 200,000 SCAP 07:50
10 200,000 JBER 07:50
10 200,000 SING 07:53
10 150,000 NUMS 07:55
10.05 150,000 CANA 07:52
10.5 200,000 STFL 07:57
11 150,000 ARDA 07:55
13.1 5,800 07:50
14 2,165 07:50
14.5 9,590 05:00
23.5 100,000 05:00
86.6 150,000 07:50
7p auction

9 Depth
6 50,000 PEEL 07:46
6 50,000 SING 07:54
6 50,000 WINS 07:52
6.2 50,000 SCAP 07:47
6.2 0 STFL 16:51
6.24 5,000 07:51
6.3 10,000 07:51
6.5 50,000 JBER 07:55
7 0 CFEP 16:51

Share this article
Development Agmnt - Autoimmune Disease Treatments
HEMOGENYX PHARMACEUTICALS PLC
Released 07:00:04 26 June 2020
RNS Number : 1362R
Hemogenyx Pharmaceuticals PLC
26 June 2020

Hemogenyx Pharmaceuticals plc

(the "Company")

Agreement for the Development of New Treatments for Autoimmune Diseases



Hemogenyx Pharmaceuticals plc is pleased to announce that it has signed a Biological Investigation and Material Supply Agreement ("Agreement") with a leading global pharmaceutical company ("GlobalCo") engaged in the research, development, manufacture and marketing of pharmaceutical products.

Under the Agreement, GlobalCo will supply the Company with certain biological materials and related confidential information in order for the Company to perform research and development activities aimed at the discovery and validation of novel materials ("Materials") to be used for the treatment of systemic lupus erythematosus ("Lupus") and possibly other autoimmune diseases.



This Agreement will fully complement the Company's own development work currently being undertaken. The Agreement stipulates certain confidential provisions, including, at this stage, the pharmaceutical company's identity. GlobalCo is the same organisation with which the Company is collaborating to develop its CDX antibody product candidate and with which it also has a research agreement for the development of the Company's humanized mice.



Under the Agreement, the Company will grant GlobalCo a research license for anything jointly developed under the Agreement, as well as an option for an exclusive worldwide license to commercially exploit jointly developed Materials. If the option is not exercised by GlobalCo, the Company will have an option to license the jointly developed Materials itself.



Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "This is a very encouraging agreement that provides additional support for our own plans for the development of novel treatments for Lupus and other autoimmune diseases. It fully complements the work that we are already undertaking with our own resources. This close collaboration offers the potential for ongoing value-adding licensing arrangements with a major pharmaceutical company with the benefit of their global reach and large-scale resources. It is gratifying to be able to report our close and developing relationship with GlobalCo."

Velocys plc

("Velocys" or the "Company")

26 June 2020

Publication of Circular

Velocys plc (VLS.L), the sustainable fuels technology company, announces that, further to its announcements on 24 and 25 June 2020, the Company will today publish the circular in connection with its fundraise (the "Circular").



The Circular will be posted to shareholders today. The full text of the Circular can also be found at www.velocys.com/investors.



Open Offer



As previously announced, the Company is providing eligible shareholders with the opportunity to subscribe for new ordinary shares (the "Open Offer Shares") in the Company by way of an open offer (the "Open Offer") at the offer price for the fundraise of 5p, pro rata to their holdings of existing ordinary shares ("Existing Ordinary Shares"). Eligible shareholders may also make applications in excess of their pro rata initial entitlement up to an amount equal to the total number of Open Offer Shares available under the Open Offer less an amount equal to such eligible shareholder's Open Offer entitlement.



The Company is providing all eligible shareholders with the opportunity to subscribe for an aggregate of up to 19,999,957 shares to raise gross proceeds of up to c.£1 million on the basis of:



3.10676 Open Offer Shares for every 100 Existing Ordinary Shares



Further details of the Open Offer, including the terms and conditions, are available to shareholders

I SAID YEST THAT THIS CHAT BOARD WOULD B INFESTED BY SCUM POSTERS ALL TELLING NEWBY INVESTORS THEY WERE INTO A CRAP SHARE , HOPEFULLY MOST HAVENT SUCCUMED TO THIS RELENTLESS BARRAGE OF ****** AND SOLD OUT . !!! THIS SHARE IS 1 OF THE BEST U WILL EVER INVEST IN .. . IF U ARE 50 % DOWN AT MO DO NOT SELL . AIM MARKET PRICE IS ALL A GAME . . HOLD A BIT LONGER AND THIS WILL ALL TURN AROUND SOON . . MAJOR PLAYERS R INVOLVED IN THIS COMPANY AND U WILL B REWARDED SOON ... GLA

hi thurg , u prob r rite but i just think this share dip is just but a tiny blip of how i see this share going . hence me just making folks think a little bit more than day 2 day shenanigans . this company is a pention pot holder imo .. gla

ha ha . everyones most detested poster . go back to ure mothers basement x

just say i was the owner of a top of the range sports club ... paying my next recruit ?170 k a week to make me happy and also giving me a bit of light relief relax time from being a billionaire .must b stressful being so wealthy . a long term investment of mine which i have invested in years ago id given up on suddenly starts to look as if it could b a world game changer !!shall i reinvest at a few pennys to get more shares . count me in . maybe i should buy the company ???

Time Trade Price Volume Value
16:38:49 7.88 700,000 55.16k buy

think the after market deals will be big

7.4

27 Depth
7.64 113,000 16:24
7.64 500 16:18
7.9 240,000 13:23
8.1 99,982 12:34
9 200,000 SCAP 12:02
9 200,000 WINS 12:02
9 150,000 PEEL 14:50
9 20,000 16:02
9.6 100,000 12:02
9.6 15,000 12:02
9.86 150,000 CANA 16:14
9.9 80,000 12:02
10 200,000 SING 14:15
10 150,000 NUMS 16:24
10 200,000 JBER 16:24
10.5 200,000 STFL 12:02
11 12,900 12:02
11 150,000 ARDA 12:02
11 150,000 CFEP 12:02
13.1 5,800 12:02
14 2,165 12:02
14.5 9,590 12:02
15 40,000 12:02
15 16,000 12:02
15 20,000 12:02
23.5 100,000 12:02
86.6 150,00 upping the ask now

yip . now offering me 7 .32 to sell

28 Depth
7.62 60,000 15:50
7.88 60,000 14:59
7.9 240,000 13:23
8.1 99,982 12:34
8.9 400 12:02
9 200,000 SCAP 12:02
9 200,000 WINS 12:02
9 150,000 PEEL 14:50
9.6 100,000 12:02
9.6 15,000 12:02
9.9 80,000 12:02
9.96 200,000 JBER 15:56
9.96 150,000 NUMS 15:56
9.96 150,000 CANA 15:56
10 200,000 SING 14:15
10.5 200,000 STFL 12:02
11 12,900 12:02
11 20,000 12:02
11 150,000 ARDA 12:02
11 150,000 CFEP 12:02
13.1 5,800 12:02
14 2,165 12:02
14.5 9,590 12:02
15 40,000 12:02
15 16,000 12:02
15 20,000 12:02
23.5 100,000 12:02
86.6 150,000 12:02
up it goes into close

just bought at 7 .298 showing as sell . everything showing as sells around this price . c where sp go after 4 30 gla

they r playing games . hardly any buys showing. tho the 7.5 s are buys and 7.42 sells

23 Depth
8.5 250,000 07:53
8.76 250,000 07:53
9 150,000 CFEP 07:50
9 200,000 SCAP 07:51
10 200,000 WINS 07:52
10 200,000 SING 07:53
11 20,000 07:53
11 12,900 07:51
11 150,000 CANA 07:56
11.5 200,000 JBER 07:50
11.8 7,640 07:50
11.8 100,000 07:53
12.5 18,000 07:50
13.05 150,000 NUMS 07:55
13.1 5,800 07:50
13.8 100,000 07:53
14 2,165 07:50
14.5 9,590 05:00
15 40,000 05:00
15 16,000 05:00
15 20,000 07:50
23.5 100,000 05:00
86.6 150,000

9p

Following admission of the new ordinary shares, Lansdowne Partners will have a holding of 196,220,153 shares in the share capital of the Company, representing approximately 18.4% of the Company's enlarged share capital assuming full take up of the Open Offer.



Director and associate participation in the Placing



The following Directors of the Company have agreed to subscribe for the number of Placing Shares opposite his/her name as set out below:



Name Number of Placing Shares



Henrik Wareborn 400,000

Andrew Morris 400,000

Philip Malcolm Holland 200,000

Darran Keith Messem 100,000

Sandy Shaw[1] 100,000

Total 1,200,000





Open Offer



Further to the announcement of its proposed open offer yesterday, the Company proposes to raise up to £1 million by way of an open offer of up to 20,000,000 new ordinary shares (the "Open Offer Shares") to eligible shareholders of the Company at the Offer Price (the "Open Offer").



The Company considers it important that, where reasonably practicable, shareholders who have not had an opportunity to take part in the Placing have an opportunity to participate in the equity fundraise at the Offer Price. The Company is therefore providing eligible shareholders with the opportunity to subscribe for Open Offer Shares at the Offer Price pursuant to the Open Offer, pro rata to their holdings of existing ordinary shares. Eligible shareholders may also make applications in excess of their pro rata initial entitlement up to an amount equal to the total number of Open Offer Shares available under the Open Offer less an amount equal to such eligible shareholder's Open Offer entitlement.



Further details of the Open Offer, including the terms and conditions, will be made available to shareholders separately in the circular to be published by the Company in connection with the Fundraise.



Circular and General Meeting



Completion of the Placing, Retail Offer and Open Offer (together, the "Fundraise") is conditional (amongst other things) upon the passing of certain resolutions. A General Meeting is therefore being convened for the purpose of considering the Resolutions at 10.30 a.m. on 14 July 2020 at Magdalen Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford OX4 4GA. Notice of the General Meeting is set out in the Circular.



On 11 May 2020, the UK Government announced the Stay Alert Guidance. The Stay Alert Guidance prohibits, among other things, certain public gatherings. The General Meeting has been arranged on the ass